683 related articles for article (PubMed ID: 33509252)
1. Antibody-drug conjugates in solid tumors: a look into novel targets.
Criscitiello C; Morganti S; Curigliano G
J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
Chu Y; Zhou X; Wang X
J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
4. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
Tarantino P; Carmagnani Pestana R; Corti C; Modi S; Bardia A; Tolaney SM; Cortes J; Soria JC; Curigliano G
CA Cancer J Clin; 2022 Mar; 72(2):165-182. PubMed ID: 34767258
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò E; Zagami P; Curigliano G
Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
[TBL] [Abstract][Full Text] [Related]
9. The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads.
Boni V; Sharma MR; Patnaik A
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-17. PubMed ID: 32315240
[TBL] [Abstract][Full Text] [Related]
10. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
11. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
12. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
14. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
15. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
[TBL] [Abstract][Full Text] [Related]
16. Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors.
Nelson BE; Meric-Bernstam F
Annu Rev Med; 2024 Jan; 75():31-48. PubMed ID: 37758237
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload.
Kondrashov A; Sapkota S; Sharma A; Riano I; Kurzrock R; Adashek JJ
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631374
[TBL] [Abstract][Full Text] [Related]
18. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
